Dr. Brawman-Mintzer and Colleagues Reply to "Sedative Effects of Low-Dose Risperidone in GAD Patients and Risk of Drug Interactions"

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We appreciate the comments of Drs. Kopecek, Mohr, and Novak in response to our report suggesting that risperidone at low doses may represent a useful tool in the management of symptomatic GAD patients.¹ Two issues are brought to our attention that were only marginally addressed in the original report.

First, the possibility is raised that risperidone could have contributed to the somnolence experienced by some patients.’ ‹